Company News
Allogene Therapeutics Shares Rise 36% on Trial
Allogene Therapeutics shares jumped 36% after interim ALPHA3 trial showed 58.3% MRD clearance versus 16.7% in control.
The trial’s futility analysis revealed a 41.6% absolute MRD clearance gap, surpas
